Friday, 14 Dec 2018

You are here

CIRT Trial - Methotrexate Fails at Cardiovascular Prevention

Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.

The CIRT trial was prematurely halted in April 2018 as the Data Safety Monitoring Board judged that MTX was unable to  prevent CV events and that continuation would not likely favorably change these outcomes.

The study was published in the NEJM and presented at American Heart Association meeting in Chicago.

The large Cardiovascular Inflammation Reduction trial (CIRT) was funded by the NHLBI and halted based on a recommendation from the trial's Data and Safety Monitoring Board. This was a cardiovascular intervention trial and did not involve patients with RA or arthritis. 

This was a randomized, double-blind trial of low-dose MTX (escalated to 15 to 20 mg weekly) vs. placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease (stable atherosclerosis) who additionally had either type 2 diabetes or the metabolic syndrome. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death or unstable angina that led to urgent revascularization.

After 2.3 years the trial was stopped. The primary endpoint occurred equally in those treated with MTX (n=201) or placebo (n=207) (hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). At the final visit, the mean MTX dose was roughly 19 mg/week but roughly 1 in 5 patients had permanently discontinued the trial regimen.

Compared with placebo, MTX treated patients had more liver enzyme elevations, leukopenia, higher MCV values, more  anemia and non–basal-cell skin cancers. MTX patients also had more oral ulcers and unintended weight loss. 

Additionally MTX did not significantly lower interleukin-1β, interleukin-6, or C-reactive protein levels than placebo. 

These findings are surprising in light of the success of the CANTOS trial wherein canakinumab (an IL-1 inhibitor) significantly lowered CV events in high risk CV patients. 

One difference between trials is that the CANTOS trial enrolled patients with a prior myocardial infarction and elevated high sensitivity C-reactive protein (CRP) of 2.0 mg/L or more.  The mean entry CRP levels were lower in CIRT compared to CANTOS (~1.5 vs 4.5 mg/L) and statins were used by >85% of patients in both trials.  Yet, the CANTOS trial showed canakinumab to lower IL-1 and CRP levels while demonstrating significantly fewer CV events, CVA and cancer deaths.  Nevertheless, the FDA has denied Novartis application to use canakinumab in cardiac prevention by issuing a complete response letter (rejection). 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No End in Sight for the Shingrix Vaccine Shortage

There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection. 

Since its FDA approval nearly a year ago, sales of the new vaccine have outperformed projections and are expected to approach $1 billion in revenue for 2018. 

Patients Don't Always Tell the Truth

Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.

Deprescribing to Battle Polypharmacy

The Gerontological Society of America has published a report calling for deprescribing as a means of managing polypharmacy in the elderly.

Limited Impact of Vitamin D Supplementation

A systematic review of 81 studies on vitamin D concludes that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density.

Metanalyses specifically looked at studies addressing total or hip fractures, falls, or bone mineral density measured at the lumbar spine, total hip, femoral neck, total body, or forearm.

Steroid Injection Superior to Splinting in Carpal Tunnel Syndrome

Lancet has published a comparative effectiveness study examining the the value of night splints (conservative treatment) vs local injection for patients with carpal tunnel syndrome.